Form 4: UroGen Pharma Officer Sells Shares Under 10b5-1 Plan

UroGen Pharma's Chief Medical Officer, Mark Schoenberg, has sold 10,000 ordinary shares for approximately $400,000 as part of a pre-arranged trading plan.

Summary

• Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), reported a transaction on July 9, 2026.
• He sold 10,000 ordinary shares.
• The sale was executed under a Rule 10b5-1(c) trading plan adopted on August 15, 2025.
• This transaction represents the final sale under that specific trading plan.
• The shares were sold at a weighted average price of $40.00, with individual transactions ranging from $40.00 to $40.02.
• The total value of the sale is approximately $400,000.
• Following this transaction, Schoenberg beneficially owns 119,763 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While an insider sale can be a negative signal, the adherence to a Rule 10b5-1 plan and the fact that it's the final sale under that plan mitigates significant concern.

Positives

• The sale was conducted under a pre-established Rule 10b5-1(c) trading plan, indicating adherence to a structured and compliant selling strategy.
• The transaction was the final sale under the plan, potentially signaling the conclusion of a planned divestment period.
• The reporting person retains a significant number of shares (119,763) after the sale.

Negatives

• A significant number of shares (10,000) were sold by a key executive.
• The sale represents a reduction in the reporting person's direct beneficial ownership.

Risks

• While the sale is under a 10b5-1 plan, large sales by insiders can sometimes be perceived negatively by the market, potentially impacting share price.
• The filing does not provide context on the reasons for the sale beyond the trading plan, leaving room for speculation.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports a past transaction by an insider.

Management Comments

• The transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c).
• The adoption date of the referenced Rule 10b5-1(c) plan is August 15, 2025.
• This transaction represents the final sale under such trading plan.
• The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price within the range upon request.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan is a common and legally recognized method for executives to sell shares without facing accusations of insider trading, provided the plan is established when the executive does not possess material non-public information. The sale of shares by a Chief Medical Officer, while routine under a 10b5-1 plan, is always closely watched by investors.

Stakeholder Impact

• Shareholders: May interpret the sale as a sign of reduced confidence by management, although the 10b5-1 plan mitigates this concern. The retention of a significant number of shares by the executive is a positive counterpoint.
• Employees: Similar to shareholders, the impact is likely minimal due to the structured nature of the sale.
• Management: The executive has complied with regulatory requirements for share sales.

Next Steps

• The reporting person has completed their planned sales under the August 15, 2025, Rule 10b5-1 plan.
• The company may receive requests for detailed pricing information regarding the sale.

Key Dates

Keywords

UroGen Pharma, URGN, Form 4, Insider Trading, Rule 10b5-1, Share Sale, Mark Schoenberg, Chief Medical Officer, Beneficial Ownership, Securities Exchange Act